摘要
目的系统评价外周血前列腺癌抗原3(PCA3)基因检测对前列腺癌的诊断效能。方法计算机检索Medline,Embase,Cochrane Library,CNKI和WANFANG等国内、外数据库至2018年12月,应用RevMan5.0,Meta-Disc1.4和Stata12.0软件进行meta分析。结果1060例受试者共纳入11项研究。结果显示,外周血PCA3检验诊断前列腺癌的敏感度和特异度分别为0.58,95%CI[0.53,0.63]和0.94,95%CI[0.92,0.96],阳性似然比、阴性似然比分别为8.96,95%CI[5.22,15.40]和0.32,95%CI[0.16,0.67];ROC曲线下面积为0.9379±0.0346,Q指数为0.8749±0.0433。结论外周血PCA3基因检测诊断前列腺癌特异度较高,但敏感度一般,具有排除诊断的能力,需对该检测方法进一步评价。
Objective To evaluate validity of peripheral blood PCA3 test for diagnosis of prostate cancer.Methods By searching literature published in Medline,Embase,Cochrane Library,CNKI and WANFANG database by combining with MeSH and free words,set deadline at December 2018,used Review Manager 5.0,Meta-Disc1.4 and Stata 12.0 software to perform meta-analysis.Results 11 studies including 1 060 subjects were included in meta-analysis.The sensitivity was equal to 0.58,95%CI[0.53,0.63],specificity was equal to 0.94,95%CI[0.92,0.96],positive likelihood ratio was equal to 8.96,95%CI[5.22,15.40],negative likelihood ratio was equal to 0.32,95%CI[0.16,0.67],AUC was equal to 0.937 9±0.034 6 and the Q index was equal to 0.874 9±0.043 3.Conclusion The peripheral blood PCA3 test for diagnosing prostate cancer is high specificity but moderate sensitivity,it has the ability to exclude diagnosis,but not clear to confirm prostate cancer.
作者
闫瑾
李小珍
杨飞
YAN Jin;LI Xiao-zhen;YANG Fei(Department of Health and Physical Examination,the Second Affiliated Hospital of Xi’anJiaotong University,Xi’an 710004,China;Department of Urology Research Institute,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
出处
《现代检验医学杂志》
CAS
2019年第5期40-44,51,共6页
Journal of Modern Laboratory Medicine
